The funding is intended to support a study entitled “Comparison of Minimally Invasive Keyhole Craniotomy and Stereotactic Radiosurgery for the Treatment of New Brain Oligometastases: A Prospective, Open Label Study”
“The AUA is one of our biggest opportunities each year to share the latest information about brachytherapy with the urological community,” said Thomas LaVoy, Chairman and Chief Executive Officer of IsoRay, Inc.
The Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room, thereby allowing clinicians to individualize the procedure to the patient’s anatomy in real time.
Revenue for the third quarter of fiscal 2018 was $1.57 million, a 23% increase compared to revenue of $1.28 million for the third quarter of fiscal 2017 and a 2% increase compared to revenue of $1.54 million in the second quarter of fiscal 2018.
Tom LaVoy, IsoRay’s CEO, will also be a participant on a panel discussion at 1:45pm EDT entitled “Disruptive Injectables & Oncology”.
©2023. All rights reserved. Terms & Privacy | Privacy Policy
